معرفی
Yibin Kang is the Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University, an Associate Director of the Rutgers Cancer Institute of New Jersey, and a founding member of the Ludwig Institute for Cancer Research Princeton Branch. He earned his bachelor's degree from Fudan University (1995), a PhD from Duke University (2000), and completed postdoctoral training at Memorial Sloan-Kettering Cancer Center. His research focuses on breast cancer metastasis mechanisms, including tumor-stromal interactions, cancer stem cells, and therapeutic development. Dr. Kang has authored over 200 publications and received numerous accolades, including the AACR Award, Vilcek Prize, and AAAS Fellowship.
Education:
- Bachelor’s degree, Fudan University (1995)
- PhD in Molecular Biology, Duke University (2000)
Research Interests: Dr. Kang’s work explores molecular mechanisms driving metastasis, immune evasion, and treatment resistance in breast cancer. His lab investigates tumor microenvironment dynamics, cancer stem cell regulation, and drug development targeting metastatic pathways. Recent studies highlight the role of microbiome metabolism, macrophageal niches, and biomolecular condensates in cancer progression.
Publications: His recent work emphasizes metabolic reprogramming, EMT plasticity, and therapeutic targeting of MTDH-SND1 complexes. Articles focus on translating molecular insights into clinical strategies, such as PI3K inhibitor efficacy modulation and bone metastasis suppression via niche modulation.
Awards:
- American Cancer Society Research Scholar Award (2005)
- Department of Defense Era of Hope Scholar Award (2006)
- 2011 Vilcek Prize for Creative Promise in Biomedical Sciences
- AACR Award for Outstanding Achievements (2012)
- Fidler Innovation Award (2014), Fuller Albright Award (2014), AACR Outstanding Investigator Award (2014)
- AAAS Fellow (2016), American Cancer Society Research Professor (2019)
Grants & Teams: As a leader in metastasis research, Dr. Kang chairs key AACR committees and directs interdisciplinary projects at the Ludwig Institute. His lab collaborates on preclinical models of bone metastasis and develops novel therapies targeting tumor-stromal interactions.
Labs/Teams: His research group at Princeton integrates molecular biology, pharmacology, and systems biology to address metastasis at the Ludwig Institute and Rutgers Cancer Institute.
